天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.

LY3200882

  Cat. No.:  DC10675   Featured
Chemical Structure
1898283-02-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
LY3200882 is a novel, highly selective TGFβRI small molecule inhibitor.
Cas No.: 1898283-02-7
Chemical Name: 2-(4-((4-((1-Cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol
Synonyms: LY3200882;19HY34R6UN;2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol;2-{4-[(4-{[1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy}pyridin-2-yl)amino]pyridin-2-yl}propan-2-ol;LY 3200882;BCP20882;s8772;A16816;C1(CC1)N1N=C(C(=C1)OC1=CC(=NC=C1)NC1=CC(=NC=C1)C(C)(C)O)C1CCOCC1;2-[4-[[4-[1-Cyclopropyl-3-(oxan-4-yl)pyrazol-4-yl]
SMILES: O1C([H])([H])C([H])([H])C([H])(C([H])([H])C1([H])[H])C1C(=C([H])N(C2([H])C([H])([H])C2([H])[H])N=1)OC1C([H])=C([H])N=C(C=1[H])N([H])C1C([H])=C([H])N=C(C=1[H])C(C([H])([H])[H])(C([H])([H])[H])O[H]
Formula: C24N5O3H29
M.Wt: 435.5188
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: LY3200882 is a novel and highly selective inhibitor of TGF-β receptor type 1 (TGFβRI).
Target: TGFβRI[1]
In Vivo: LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vivo in subcutaneous tumors in a dose dependent fashion. LY3200882 has shown anti-metastatic activity in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer)[1].
In Vitro: LY3200882 is a novel, highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vitro in tumor and immune cells. LY3200882 has shown anti-metastatic activity in vitro in migration assays. In in vitro immune suppression assays, LY3200882 has shown the ability to rescue TGFβ1 suppressed or T regulatory cell suppressed na?ve T cell activity and restore proliferation[1].
References: [1]. Huaxing Pei, et al. Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor. AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 955.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC10675 LY3200882 LY3200882 is a novel, highly selective TGFβRI small molecule inhibitor.
X